List of our valuable Partners
Address: 56 Gameat El Dowal El Arabia St, (Mohandeseen Administrative Tower 20th, Floor) Mohandeseen,Giza ,Egypt
Follow Us:
CHEPLAPHARM
As a global specialty pharmaceutical company headquartered in Germany, their mission is to be a sustainable platform for well-established and trusted pharmaceutical brands.
KENSINGTON PHARMA
Kensington Pharma specialises in the innovation, identification and development of niche generic medicines for use in the secondary care hospital environment.
With a dynamic team of professionals, we recognise the needs of the market and strive to offer affordable dependable solutions. By investing in the development of generic injectables we aim to facilitate stability and cost effectiveness for the NHS.
have a wealth of knowledge and experience in the pharmaceutical industry from regulation to distribution assuring the quality and integrity of our products throughout.
SERB
we are a growing pharmaceutical company and a dedicated ally to healthcare providers treating patients with critical conditions.
Our portfolio of products, many of them lifesaving, is focused on emergency care and rate diseases.
Our expertise lies in mastering complex products, navigating complicated regulatory pathways, and serving niche patient populations.
Emergency Care: SERB has the broadest antidote portfolio in the world, including medical countermeasures for chemical, biological, radiological and nuclear (CBRN) risks. This makes us a trusted partner and one-stop-shop for hospitals, emergency services, health departments, and governments.
Rare Diseases: Our growing rare disease portfolio helps patients with rare neurologic syndromes, metabolic disorders, and rare conditions in oncology. We work to help these patients get the diagnosis they need and access to the treatment options they deserve. This “patient first” culture has helped us to build long-term relationships with the patient groups and key opinion leaders.
HEYL
Our company HEYL Chemisch-pharmazeutische Fabrik GmbH & Co.KG is a fully independent family business, that has had its head office in Berlin since its establishment in 1926. In cooperation with our international subsidiaries, our main focus is the licensing and marketing of pharmaceuticals, as well as the sales and distribution of pharmaceutical ingredients and specialty chemicals.
Our expertise lies in the specialty areas and niches. That is why, in collaboration with national and international research institutions and universities, we have developed a number of antidotes. These are highly effective drugs that are used for treating poisonings from thallium, arsenic, heavy metals (mercury, lead) or radioactive isotopes such as cesium or plutonium. The demands we receive from all over the world show the uniqueness and the medical importance of these pharmaceuticals.
The majority of the pharmaceutical ingredients of these antidotes are produced in accordance with current quality controls, by our subsidiary in Thuringia, Laborchemie Apolda GmbH. Our two sites in the USA and Japan, the Heyltex Corporation in Houston, Texas and Heyl Japan & Co. Ltd. in Tokyo, represent our company in important foreign markets.
Berlin is both the German and international headquarters of the HEYL Chemisch-pharmazeutische Fabrik. Here, longstanding marketing expertise unites with medical and scientific know-how in five strategic main business areas: Poisonings, Morbus Wilson, rheumatoid arthritis, toxoplasmosis, and specific vitamin deficiencies.
The company HEYL will always continue to strive for the utmost therapeutic efficiency and safety of their pharmaceuticals. Just as it has been doing so for many years, further developments of the compounds will be achieved in close cooperation with national and international research institutions and universities. By focusing on specialty areas and niches, along with a science-based marketing approach, HEYL and its employees in Berlin and Apolda aim to continue to strongly remain an independent family business with a long line of tradition.
GENERIS
reated in 2002, Generis® quickly became a leading company in Portugal in the generic medicines market. In 2006, it acquired its first manufacturing facility, with the aim of implementing a solid and sustained growth strategy. Today, Generis® is part of the Aurobindo Group, present in more than 20 countries, vertically integrated from R&D to commercialization. The Group has 26 factories with the latest equipment and exports to more than 150 countries.
RECORDATI
Everything we do is driven by the needs of people who have a rare disease:
Our team believes that each person with a rare disease has the right to the best treatment.
We have nearly 30 years’ experience in bringing orphan drugs to market for rare diseases, with a portfolio of 18 products and a significant research and development program.
We help to develop, and work alongside, global networks of patients, patient groups, experts, healthcare professionals, scientists, policy makers and regulators.
We employ professionals in over 30 countries, and are rapidly expanding globally.
We have unparalleled experience in the development of clinical trials for orphan drugs and in specialist regulatory requirements.
Our infrastructure has been developed to uniquely produce, package and distribute very small to high numbers of specialist products worldwide.
Recordati Rare Diseases is committed to improving the diagnosis and management of rare diseases through our educational work and the Recordati Rare Diseases Foundation.
TECNIMEDE GROUP SRL PORTUGAL
TECNIMEDE GROUP is composed by pharmaceutical companies of private and 100% Portuguese capital.
Started its activity in 1980 and covers the entire life cycle of the medicinal products for human use — development, manufacture, promotion and marketing.
TECNIMEDE GROUP’s strategy is based on a strong investment in Research, Development and Production of Medicinal Products.
It is intended that the results obtained allow to consolidate the Group’s position in the Portuguese market and to strengthen exports and internationalization. Atlantic Pharma Brazil and Atlas Pharm (Morocco) are an example of the Group’s expansion and development of manufacturing plants.
TECNIMEDE GROUP’s portfolio includes more than 100 products, as a result of its R&D center, which results in more than 2,500 MAs worldwide.
Pharmis Biofarmacêutica – PORTUGAL.
Pharmis is a privately owned pharmaceutical company, established in 1991, which is focused on development, marketing and sales of hospital products. The company is based in Portugal, with wholly owned subsidiaries in Spain and Brazil.
The company markets a range of branded products, licensed from multinational companies, and generic injectables, which have been developed by Pharmis and their partners.
Pharmis has more recently committed to investing in biotechnology and developing its own pipeline of biological therapeutic products for oncology.
MEDICE- GERMANY
MEDICE is one of the most successful family-owned pharmaceutical companies in Germany. Committed to the fundamental ethical values of medicine, MEDICE has been demonstrating for 65 years that humanity and confidence are a strong basis for innovation and growth.
TECNOPHARMA SRL ITALY
TECNOPHARMA SRL is an agile European company, registered under the Italian jurisdiction, with headquarters in the city of Genoa.
It is an enterprise oriented towards the research of new methods to preserve and recover patients’ health. Also it deals with the development of drugs, in innovative and more functional pharmaceutical ways, in order to guarantee greater quality with less waste. It Produces and markets drugs both as a “brand” and as an “International Common Denomination” (ICD), Also known as “drugs with generic formula.”
These aim at reaching and guaranteeing the right to health to the highest Possible number of patients by harmonizing at best their scientific discoveries.
XEPTAGEN SpA – ITALY
XEPTAGEN SpA is engaged in the discovery and clinical validation of novel molecular markers for cancer early detection, monitoring, and evaluation of response to therapy.
their mission is to improve the clinical management of cancer patients by creating innovative diagnostic tools that may allow a personalized treatment.
The Egyptian Pharmaceutical Trading Company –EGYPT.
The Egyptian Pharmaceutical Trading Company is a subsidiary/affiliate of the holding company for the pharmaceutical companies. It is one of the largest distributing companies of local and imported drugs, children dairy and supported drugs to insure distributive justice.
It was established on 1/7/1965 with a capital of one million pounds and sales of the amount of 17.35 million pounds and the number of clients about 1,000 customers.
And since then it has witnessed a huge evolution/development in all activities till its sales reached 5.16 billion in 30/6/2014. The company deals with 6573 medicinal drugs for 267 foreign, local and commercial companies.
Laboratorios Rubió, S.A – SPAIN
Laboratorios Rubió was founded in 1968 by SALVADOR AND PELAYO RUBIÓ, with the goal of selling medication that at that time were not available on the market in SPAIN
Over nearly the last 50 years, the company has launched important medicines and medical devices, with high added value, on the market which has led to a significant improvement to patients’ survival and quality of life.
FAR.G.IM. s.r.l. – ITALY
About: The FAR.G.IM. s.r.l. Was founded in 1999 with the aim to achieve and manage the A.I.C. of pharmaceutical products, relying on the market to other companies.
In 2004, acquired the assets of New Farma, one of the dealerships sales and manages the distribution of its own products and exclusive license to sell.
Following this acquisition, the business of FAR.G.IM. s.r.l. extended supplements and dermal cosmetics.
Currently, the major industry of the company is the supply of medicines to hospitals and nursing homes private with exclusive of certain drugs.
Pharmis Biofarmacêutica – PORTUGAL.
Pharmis is a privately owned pharmaceutical company, established in 1991, which is focused on development, marketing and sales of hospital products. The company is based in Portugal, with wholly owned subsidiaries in Spain and Brazil.
The company markets a range of branded products, licensed from multinational companies, and generic injectables, which have been developed by Pharmis and their partners.
Pharmis has more recently committed to investing in biotechnology and developing its own pipeline of biological therapeutic products for oncology.
© ONCOPHARM 2024